BenevolentAI and AstraZeneca Collaborate on New Lupus Target
BenevolentAI and AstraZeneca collaborate to add a novel lupus target to the discovery portfolio, aiming to identify new therapeutic targets for complex diseases.
This news matters as it highlights a significant collaboration between BenevolentAI and AstraZeneca, focusing on the addition of a novel lupus target to AstraZeneca's discovery portfolio. The collaboration aims to identify and validate new therapeutic targets for lupus and other complex diseases, which could lead to potential breakthroughs in treatment.
